|
|
|
|
|
|
|
Vascular Biogen. Ord (VBLT)
|
|
2.225 0.075 (3.49%)
|
04-18 16:00
|
|
Open:
|
2.2
|
Pre. Close:
|
2.15
|
|
High:
|
2.25
|
Low:
|
2.15
|
|
Volume:
|
85,116
|
Market Cap:
|
67M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
2.251 - 2.262
|
2.262 - 2.273
|
|
Low:
|
2.124 - 2.136
|
2.136 - 2.147
|
|
Close:
|
2.202 - 2.22
|
2.22 - 2.238
|
|
|
|
Technical analysis (as of: 2018-04-18 4:45:18 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.
|
|
Target:
|
Six months: 2.66  One year: 2.86
|
|
Support:
|
Support1: 2.01 Support2: 1.67
|
|
Resistance:
|
Resistance1:
2.28 Resistance2: 2.45
|
|
Pivot:
|
2.22
|
|
Moving Averages:
|
MA(5): 2.27 MA(20): 2.26
MA(100): 5.57 MA(250): 5.51
|
|
MACD:
|
MACD(12,26):
-0.45 Signal(12,26,9): -0.59
|
|
%K %D:
|
%K(14,3): 45.69 %D(3): 58.80
|
|
RSI:
|
RSI(14): 32.77
|
|
52-Week:
|
High: 9.05
Low: 2.005 Change(%): -57.2
|
|
Average Vol(K):
|
3-Month: 39708
10-Days 19833
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.VBLT has closed below upper band by 49.1%. Bollinger Bands are 81.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to VBLT's normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-03-15T14:40:04-04:00
VBL Therapeutics' (VBLT) CEO Dror Harats on Q4 2017 Results - Earnings Call Transcript
2018-03-15T09:30:06-04:00
VBL Therapeutics reports FY 2017 results
2018-03-15T07:18:21-04:00
VBL Therapeutics reports FY results
2018-03-13T11:53:32-04:00
VBL Fails Phase 3 Brain Cancer Study, Should Be Avoided
2018-03-12T08:00:00-04:00
3 Things In Biotech, March 11: Aradigm Retries, Pfizer Glides, VBL Crashes
2018-03-09T16:20:49-05:00
Biotech Forum Daily Digest For March 9th
2018-03-09T11:51:14-05:00
Your Daily Pharma Scoop: Progenics Rallies, Merck To Partner With Eisai, Teva Upsizes Debt Offering
2018-03-09T08:12:01-05:00
Premarket analyst action - healthcare
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
